Tyra Biosciences Files 8-K Report

TL;DR

Tyra Biosciences dropped an 8-K, likely with news. Check for details.

AI Summary

On October 28, 2024, Tyra Biosciences, Inc. filed an 8-K report. The filing indicates an "Other Events" item, but the specific details of this event are not elaborated upon in the provided text. The company is incorporated in Delaware and its principal executive offices are located in Carlsbad, California.

Why It Matters

This filing signals a material event has occurred for Tyra Biosciences, requiring public disclosure. Investors should look for further details to understand the nature and impact of this event.

Risk Assessment

Risk Level: medium — The filing of an 8-K often indicates significant corporate events, which can introduce uncertainty and impact stock price.

Key Numbers

• 001-40800 — SEC File Number (Identifies the company's filing with the SEC.)
• 83-1476348 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Tyra Biosciences, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of Incorporation
• Carlsbad, California (location) — Principal Executive Offices
• October 28, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share TYRA Nasdaq Global Select

Filing Documents

• d895225d8k.htm (8-K) — 29KB
• 0001193125-24-244590.txt ( ) — 150KB
• tyra-20241028.xsd (EX-101.SCH) — 3KB
• tyra-20241028_lab.xml (EX-101.LAB) — 18KB
• tyra-20241028_pre.xml (EX-101.PRE) — 11KB
• d895225d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements Tyra cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the company's current beliefs and expectations and include, but are not limited to: expected initiation of the BEACH301 study and the timing thereof; the design and goals of the BEACH301 study; expected submission of an IND for NMIBC and the timing thereof; and the potential safety and therapeutic benefits of TYRA-300. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in the company's business, including, without limitation: later developments with the FDA may be inconsistent with prior feedback from the FDA, including with respect to the proposed initiation and design of the company's planned Phase 2 study of TYRA-300 in achondroplasia; the company is early in its development efforts and has only recently begun testing TYRA-300 and TYRA-200 for oncology in clinical trials, and the approach the company is taking to discover and develop drugs based on the company's SNP platform is novel and unproven and it may never lead to product candidates that are successful in clinical development or approved products of commercial value; potential delays in the commencement, enrollment, data readouts and completion of preclinical studies and clinical trials; results from preclinical studies or early clinical trials not necessarily being predictive of future results; interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, as follow-up on the outcome of any particular patient continues and as more patient or final data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment af

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TYRA BIOSCIENCES, INC. Date: October 28, 2024 By: /s/ Ali Fawaz Ali Fawaz General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR